Peripheral neuropathy in adult type 1 Gaucher disease: A 2-year prospective observational study

Brain

Volumn 133, Issue 10, 2010, Pages 2909-2919

  Biegstraaten, Marieke ^a   Mengel, Eugen ^b   Maródi, Laszlo ^c   Petakov, Milan ^d   Niederau, Claus ^e   Giraldo, Pilar ^f   Hughes, Derralyn ^g   Mrsic, Mirando ^h   Mehta, Atul ^g   Hollak, Carla E M ^a   Van Schaik, Ivo N ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d CLINICAL CENTER OF SERBIA   (Serbia)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h KBC Zagreb   (Croatia)

Author keywords

EMG; Gaucher disease; incidence; peripheral neuropathy; prevalence

Indexed keywords

GLUCOSYLCERAMIDASE; TOXIN;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CUBITAL TUNNEL SYNDROME; DISEASE DURATION; ELECTROPHYSIOLOGY; ENZYME REPLACEMENT; EXPOSURE; FEMALE; FOLIC ACID DEFICIENCY; FOLLOW UP; GAUCHER DISEASE; HUMAN; KIDNEY FAILURE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MONONEUROPATHY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY MOTOR AXONAL POLYNEUROPATHY; THIAMINE DEFICIENCY; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; ELECTRODIAGNOSIS; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE;

ADOLESCENT; ADULT; AGED; ELECTRODIAGNOSIS; FEMALE; GAUCHER DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PATIENT SELECTION; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; PROSPECTIVE STUDIES;

EID: 77957680068     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq198     Document Type: Article

References (57)

1. Agresti A, Caffo B. Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am Stat 2000; 54: 280-8.
2. Albers JW, Garabrant DH, Schweitzer S, Garrison RP, Richardson RJ, Berent S. Absence of sensory neuropathy among workers with occupational exposure to chlorpyrifos. Muscle Nerve 2004; 29: 677-86.
3. Baldereschi M, Inzitari M, Di Carlo A, Farchi G, Scafato E, Inzitari D. Epidemiology of distal symmetrical neuropathies in the Italian elderly. Neurology 2007; 68: 1460-7.
4. Beghi E, Simone P, Apollo F, Di Viesti P, Treviso M, Tonali P. Polyneuropathy in an adult hospital population. Assessment of the prevalence through a simple screening procedure. Neuroepidemiology 1988; 7: 23-8.
5. Beghi E, Monticelli ML. Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation of risk factors for poly-neuropathy in two Italian communities. Italian General Practitioner Study Group (IGPST). J Clin Epidemiol 1998; 51: 697-702.
6. Beutler E. Gaucher disease. Curr Opin Hematol 1997; 4: 19-23.
7. Bharucha NE, Bharucha EP, Dastur HD, Schoenberg BS. Pilot survey of the prevalence of neurologic disorders in the Parsi community of Bombay. Am J Prev Med 1987; 3: 293-9.
8. Bharucha NE, Bharucha AE, Bharucha EP. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology 1991; 41: 1315-7.
9. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE. 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 2008; 31: 337-49.
10. Capablo JL, Saenz de Cabezón A, Fraile J, Alfonso P, Pocovi M, Giraldo P. Spanish Group on Gaucher Disease. Neurological evaluation of patients with Gaucher disease diagnosed as type 1. J Neurol Neurosurg Psychiatry 2008; 79: 219-22.
11. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160: 2835-43.
12. Chroni E, Georgiou S, Polychronopoulos P, Sagriotis A, Monastirli A, Pasmatzi E, et al. Peripheral large nerve fibre function in patients with chronic plaque psoriasis. Eur J Neurol 2007; 14: 18-20.
13. Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 1997; 10: 657-89.
14. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hreb?́cek M, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481-5.
15. Cox TM, Aerts JM, Andria G, Belmatoug N, Bembi B, Chertkoff R, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 2003; 26: 513-26.
16. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004; 21: 976-82.
17. Davis LE, Eisen SA, Murphy FM, Alpern R, Parks BJ, Blanchard M, et al. Clinical and laboratory assessment of distal peripheral nerves in Gulf War veterans and spouses. Neurology 2004; 63: 1070-7.
18. Donofrio PD, Albers JW. AAEM minimonograph #34: polyneuropathy: classification by nerve conduction studies and electromyography. Muscle Nerve 1990; 13: 889-903.
19. Finnerup NB, Sindrup SH, Jensen TS. Chronic neuropathic pain: mechanisms, drug targets and measurement. Fundam Clin Pharmacol 2007; 21: 129-36.
20. De Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 2008; 87: 439-49.
21. Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990; 131: 633-43.
22. Gaist D, Garc?́a Rodŕguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001; 56: 931-3.
23. Gielchinsky Y, Elstein D, Green R, Miller JW, Elstein Y, Algur N, et al. High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population. Br J Haematol 2001; 115: 707-9.
24. Grabowski GA, Horowitz M. Gaucher's disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol 1997; 10: 635-56.
25. Hall KE, Liu J, Sima AA, Wiley JW. Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol 2001; 86: 760-70.
26. Halperin A, Elstein D, Zimran A. Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease? Acta Neurol Scand 2007; 115: 275-8.
27. IGPSG. Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Neurology 1995; 45: 1832-6.
28. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. Muscle Nerve 1991; 14: 1103-9.
29. Lehtinen JM, Uusitupa M, Siitonen O, Pyö rä lä K. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 1989; 38: 1307-13.
30. Leite AC, Mendonça GA, Serpa MJ, Nascimento OJ, Araújo AQ. Neurological manifestations in HTLV-I-infected blood donors. J Neurol Sci 2003; 214: 49-56.
31. Lloyd-Evans E, Pelled D, Riebeling C, Bodennec J, de-Morgan A, Waller H, et al. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem 2003; 278: 23594-9.
32. Lopate G, Pestronk A, Al-Lozi M, Lynch T, Florence J, Miller T, et al. Peripheral neuropathy in an outpatient cohort of patients with Sjö gren's syndrome. Muscle Nerve 2006; 33: 672-6.
33. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123 (Pt 4): 665-76.
34. MacKenzie JR, LaBan MM, Sackeyfio AH. The prevalence of peripheral neuropathy in patients with anorexia nervosa. Arch Phys Med Rehabil 1989; 70: 827-30.
35. Manschot SM, Biessels GJ, Rutten GE, Kessels RP, Gispen WH, Kappelle LJ. Utrecht Diabetic Encephalopathy Study Group. Peripheral and central neurologic complications in type 2 diabetes mellitus: no association in individual patients. J Neurol Sci 2008; 264: 157-62.
36. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropa-thies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000; 54: 943-9.
37. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002; 72: 596-601.
38. Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol 2001; 8: 157-65.
39. Obermann M, Katsarava Z, Esser S, Sommer C, He L, Selter L, et al. Correlation of epidermal nerve fiber density with pain-related evoked potentials in HIV neuropathy. Pain 2008; 138: 79-86.
40. Olney RK. Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block. American Association of Electrodiagnostic Medicine. Muscle Nerve Suppl 1999; 8: S225-9.
41. Oluwole OS, Onabolu AO, Link H, Rosling H. Persistence of tropical ataxic neuropathy in a Nigerian community. J Neurol Neurosurg Psychiatry 2000; 69: 96-101.
42. Osuntokun BO, Schoenberg BS, Nottidge VA, Adeuja A, Kale O, Adeyefa A, et al. Research protocol for measuring the prevalence of neurological disorders in developing countries. Results of a pilot study in Nigeria. Neuroepidemiology 1982; 1: 143-53.
43. Parry O, Mielke J, Latif AS, Ray S, Levy LF, Siziya S. Peripheral neuropathy in individuals with HIV infection in Zimbabwe. Acta Neurol Scand 1997; 96: 218-22.
44. Pastores GM, Barnett NL, Bathan P, Kolodny EH. A neurological symptom survey of patients with type I Gaucher disease. J Inherit Metab Dis 2003; 26: 641-5.
45. Al Rajeh S, Bademosi O, Ismail H, Awada A, Dawodu A, al-Freihi H, et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology 1993; 12: 164-78.
46. Rosén I, Haeger-Aronsen B, Rehnström S, Welinder H. Neurophysiological observations after chronic styrene exposure. Scand J Work Environ Health 1978; 4 Suppl 2: 184-94.
47. Rudolph T, Farbu E. Hospital-referred polyneuropathies\causes, prevalences, clinical\and neurophysiological findings. Eur J Neurol 2007; 14: 603-8.
48. Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. Hematol Oncol 2008; 26: 55-65.
49. Tapp RJ, Shaw JE, de Courten MP, Dunstan DW, Welborn TA, Zimmet PZ. AusDiab Study Group. Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med 2003; 20: 105-13.
50. Teunissen LL, Franssen H, Wokke JH, van der Graaf Y, Linssen WH, Banga JD, et al. Is cardiovascular disease a risk factor in the development of axonal polyneuropathy? J Neurol Neurosurg Psychiatry 2002; 72: 590-5.
51. The Italian Longitudinal Study on Aging Working Group. Prevalence of chronic diseases in older Italians: comparing self-reported and clinical diagnoses. Int J Epidemiol 1997; 26: 995-1002.
52. Verhamme C, van Schaik IN, Koelman JHTM, de Haan RJ, de Visser M. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain 2009; 132: 3252-3262.
53. Vrethem M, Cruz M, Wen-Xin H, Malm C, Holmgren H, Ernerudh J. Clinical, neurophysiological and immunological evidence of polyneur-opathy in patients with monoclonal gammopathies. J Neurol Sci 1993; 114: 193-9.
54. Watters MR, Poff PW, Shiramizu BT, Holck PS, Fast KM, Shikuma CM, et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 2004; 62: 1378-83.
55. Yaksh TL. Calcium channels as therapeutic targets in neuropathic pain. J Pain 2006; 7: S13-30.
56. Zarrelli MM, Amoruso L, Beghi E, Apollo F, Di Viesti P, Simone P. Italian General Practitioner Study Group. Arterial hypertension as a risk factor for chronic symmetric polyneuropathy. J Epidemiol Biostat. 2001; 6: 409-13.
57. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A. KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31: 464-9.